Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000210166 | SCV000278392 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-01-07 | criteria provided, single submitter | clinical testing | The p.E77* pathogenic mutation (also known as c.229G>T), located in coding exon 3 of the MRE11A gene, results from a G to T substitution at nucleotide position 229. This changes the amino acid from a glutamic acid to a stop codon within coding exon 3. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV002229537 | SCV002509494 | pathogenic | Ataxia-telangiectasia-like disorder | 2025-01-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu77*) in the MRE11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MRE11 are known to be pathogenic (PMID: 23080121, 23912341). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with endometrium cancer (PMID: 26845104). ClinVar contains an entry for this variant (Variation ID: 224574). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003468973 | SCV004193866 | likely pathogenic | Ataxia-telangiectasia-like disorder 1 | 2023-03-15 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV000210166 | SCV000266188 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-11-20 | flagged submission | clinical testing |